Hyemyung Seo

List of Publications by Year
in descending order

47 papers	2,775 citations	218381 26 h-index	214527 47 g-index
48 all docs	48 docs citations	48 times ranked	4357 citing authors

#	Article	IF	Citations
1	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90.	5.8	444
2	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsonâ€™s Disease. New England Journal of Medicine, 2020, 382, 1926-1932.	13.9	298
3	Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends in Neurosciences, 2002, 25, 79-84.	4.2	181
4	Generalized brain and skin proteasome inhibition in Huntington's disease. Annals of Neurology, 2004, 56, 319-328.	2.8	164
5	Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain. Neurochemistry International, 2014, 69, 35-40.	1.9	151
6	miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiology of Aging, 2014, 35, 1712-1721.	1.5	120
7	Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model Cells. PLoS ONE, 2007, 2, e238.	1.1	110
8	Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Experimental Neurology, 2005, 193, 469-480.	2.0	106
9	Human autologous iPSCâ€“derived dopaminergic progenitors restore motor function in Parkinsonâ€™s disease models. Journal of Clinical Investigation, 2020, 130, 904-920.	3.9	102
10	Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntingtonâ€™s disease. Brain, 2015, 138, 3030-3047.	3.7	83
11	LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nature Communications, 2015, 6, 8255.	5.8	79
12	Increased DJ-1 in Urine Exosome of Korean Males with Parkinsonâ€™s Disease. BioMed Research International, 2014, 2014, 1-8.	0.9	72
13	An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. Journal of Biochemistry, 2015, 157, 485-495.	0.9	70
14	Brain cells derived from Alzheimerâ€™s disease patients have multiple specific innate abnormalities in energy metabolism. Molecular Psychiatry, 2021, 26, 5702-5714.	4.1	54
15	Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21WAF1/CIP1 expression. Molecular Brain, 2015, 8, 54.	1.3	50
16	MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. Molecular Neurobiology, 2016, 53, 95-108.	1.9	48
17	Î²-Lapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes. Free Radical Biology and Medicine, 2016, 97, 168-178.	1.3	44
18	Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimerâ€™s Disease. PLoS ONE, 2015, 10, e0136950.	1.1	42

#	Article	IF	Citations
19	A direct role of the homeodomain proteins Phox2a/2b in noradrenaline neurotransmitter identity determination. Journal of Neurochemistry, 2002, 80, 905-916.	2.1	41
20	Cell-Penetrating Peptide-Patchy Deformable Polymeric Nanovehicles with Enhanced Cellular Uptake and Transdermal Delivery. Biomacromolecules, 2018, 19, 2682-2690.	2.6	39
21	Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntingtonâ€™s disease model mice. Biochemical and Biophysical Research Communications, 2014, 443, 706-711.	1.0	37
22	Gene therapy by proteasome activator, PA28Î³, improves motor coordination and proteasome function in Huntingtonâ€™s disease YAC128 mice. Neuroscience, 2016, 324, 20-28.	1.1	36
23	Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Human Molecular Genetics, 2008, 17, 3144-3153.	1.4	35
24	Age-dependent effects of valproic acid in Alzheimerâ€™s disease (AD) mice are associated with nerve growth factor (NGF) regulation. Neuroscience, 2014, 266, 255-265.	1.1	33
25	HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice. Experimental Neurobiology, 2019, 28, 504-515.	0.7	31
26	G2385R and I2020T Mutations Increase LRRK2 GTPase Activity. BioMed Research International, 2016, 2016, 1-8.	0.9	28
27	Spatial memory testing decreases hippocampal amyloid precursor protein in young, but not aged, female rats. Neuroscience Letters, 2002, 328, 50-54.	1.0	26
28	Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. European Journal of Neuroscience, 2002, 15, 498-506.	1.2	25
29	Prediction of miRNA-mRNA associations in Alzheimerâ€™s disease mice using network topology. BMC Genomics, 2014, 15, 644.	1.2	25
30	Age-associated chromatin relaxation is enhanced in Huntingtonâ€™s disease mice. Aging, 2017, 9, 803-822.	1.4	24
31	Suppression of neuroinflammation by matrix metalloproteinase-8 inhibitor in aged normal and LRRK2 G2019S Parkinson's disease model mice challenged with lipopolysaccharide. Biochemical and Biophysical Research Communications, 2017, 493, 879-886.	1.0	18
32	Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation. Human Molecular Genetics, 2016, 26, ddw363.	1.4	17
33	Age-associated bimodal transcriptional drift reduces intergenic disparities in transcription. Aging, 2018, 10, 789-807.	1.4	15
34	Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3Î²/Î²-Catenin Signaling Pathway. Molecular Neurobiology, 2018, 55, 1607-1619.	1.9	14
35	The hAPPâ€¥YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimerâ€™s disease and Downâ€™s syndrome. Journal of Neurochemistry, 2010, 114, 1819-1826.	2.1	13
36	Reduction of Nfia gene expression and subsequent target genes by binge alcohol in the fetal brain. Neuroscience Letters, 2015, 598, 73-78.	1.0	13

#	Article	IF	Citations
37	Oxidized DJ-1 Levels in Urine Samples as a Putative Biomarker for Parkinsonâ€™s Disease. Parkinson's Disease, 2018, 2018, 1-9.	0.6	13
38	JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells. Experimental Cell Research, 2014, 328, 361-378.	1.2	11
39	Identification of cancer-specific biomarkers by using microarray gene expression profiling. Biochip Journal, 2013, 7, 57-62.	2.5	9
40	Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity. Animal Cells and Systems, 2018, 22, 273-280.	0.8	9
41	Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntingtonâ€™s Disease Mouse Model. Molecular Neurobiology, 2016, 53, 2276-2286.	1.9	8
42	Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntingtonâ€™s disease. Progress in Neurobiology, 2021, 204, 102110.	2.8	8
43	Iroquois Homeobox Protein 2 Identified as a Potential Biomarker for Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 3455.	1.8	7
44	Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntingtonâ€™s disease mouse model. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 856-868.	2.5	7
45	Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells. Nature Protocols, 2022, , .	5.5	6
46	Analysis of multiâ€omics data on the relationship between epigenetic changes and nervous system disorders caused by exposure to environmentally harmful substances. Environmental Toxicology, 2022, 37, 802-813.	2.1	5
47	Matrix Metalloproteinase-8 Inhibitor Ameliorates Inflammatory Responses and Behavioral Deficits in LRRK2 G2019S Parkinson's Disease Model Mice. Biomolecules and Therapeutics, 2021, 29, 483-491.	1.1	4